NCT02988843 2020-12-10
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
Masonic Cancer Center, University of Minnesota
Indiana University
Fondazione Michelangelo